California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $ 35 billion proposal from the Biden administration is blessed by President ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

The director of medical weight management at West Virginia University says a canceled pilot program that provided weight-loss drugs to state employees showed “incredible” results, with patients losing ...

In fact, in March 2024, with the introduction of new and popular AOMs (e.g., Ozempic, Wegovy, and Zepbound), CMS issued guidance confirming that “all drugs used for weight loss have been excluded from ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

Connecticut law requires Medicaid to cover certain weight loss drugs, but officials say it hasn't been happening due to cost ...

Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.